Wockhardt Raids Competitors To Deal With Quality-Production Problems
This article was originally published in PharmAsia News
Wockhardt has responded to a series of largely U.S. FDA actions potentially crippling its ability to sell into the vital U.S. market by replacing much of its management with people attracted from India competitors.
You may also be interested in...
Combination of antibody therapy and Gilead's Veklury fails to show potential in patients with advanced disease.
The FDA’s generic drug program yearly performance report shows that generic drug approvals declined for the first time in five years in fiscal year 2020, and the agency also reported a lower number of ANDA submissions.
While personal data security must be balanced againt the right to health, winning “trust” is the key to taking AI adoption to the next stage, says a new report focused on the European market.